Related Experiment Video

Updated: May 26, 2026

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes
11:52

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Published on: January 27, 2023

Peripheral Blood CD64 Levels Decrease in Crohn's Disease following Granulocyte and Monocyte Adsorptive Apheresis

Toshimi Chiba1, Mikiya Endo, Shoko Matsushita

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.

Case Reports in Gastroenterology
|January 6, 2012
PubMed

Insights

Granulocyte and monocyte adsorptive apheresis (GMA) reduced CD64 levels in Crohn's disease patients. This reduction correlated with decreased disease activity, suggesting GMA's therapeutic potential.

Area of Science:

  • Immunology
  • Gastroenterology
  • Medical Technology

Background:

  • Crohn's disease (CD) management often involves induction therapy.
  • Granulocyte and monocyte adsorptive apheresis (GMA) is a potential treatment for CD.
  • The impact of GMA on CD64 expression in CD patients remains unclear.

Observation:

  • CD64 expression on neutrophils was assessed before and after GMA treatment in two CD patients.
  • CD64 levels were measured using flow cytometry.
  • Crohn's disease activity was evaluated using the CD activity index (CDAI).

Findings:

  • GMA treatment led to a decrease in CD64 expression on neutrophils in both patients.
  • A significant correlation was observed between reduced CD64 levels and lower CDAI scores.
  • GMA therapy resulted in a decrease in disease activity (CDAI) in both cases.

Implications:

  • GMA may modulate neutrophil activation markers like CD64.
  • Reduced CD64 expression could be a mechanism contributing to GMA's therapeutic effect in CD.
  • Further research into GMA as an induction therapy for Crohn's disease is warranted.

Keywords:
CD64Crohn's diseaseGranulocyte and monocyte adsorptive apheresis

More Related Videos

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity08:41

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Published on: June 7, 2017

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...